Modern integrative oncology blends conventional cancer therapy with carefully selected supportive interventions to optimise outcomes and quality of life. Peptide bioregulators occupy a specific role in this framework — supporting organ function and recovery between treatment cycles, never replacing primary therapy.
During chemotherapy, peptide bioregulators have been studied for their potential to support specific organ systems under stress. Vladonix and Crystagen support thymus and lymphoid function. Vesugen supports vascular endothelium. Pinealon supports cognitive resilience often impaired during chemo-brain. Cerluten supports neurological function broadly.
These applications are supportive and adjunctive. The bioregulator literature is largely Russian and Eastern European in origin, with growing but still limited Western clinical trial coverage. Integration must therefore be cautious, transparent with the oncology team, and timed to avoid theoretical interference with active cytotoxic therapy.
Beyond active treatment, peptide bioregulators may support survivorship — helping rebuild organ function and quality of life after intensive therapy ends. This recovery phase is increasingly recognised as a critical window for integrative support, where evidence-based supplementation can meaningfully aid restoration.
PeptideComb provides educational resources and access to authentic Khavinson-lineage peptides. Always coordinate use with your oncology team and integrative medicine clinician to ensure safety and synergy with your primary treatment plan.
